Corium International (CORI) Stock Price, News & Analysis

Company Overview

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

Key Stats

• Today's Range: $12.68 to $12.68
• 50-Day Range: N/A
• 52-Week Range: $7.17 to $13.93
• Volume: N/A
• Average Volume: 577,723 shs
• Market Capitalization: $459.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CORI Stock Analysis - Frequently Asked Questions

How were Corium International's earnings last quarter?

Corium International, Inc. (NASDAQ:CORI) announced its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. The biopharmaceutical company earned $7.67 million during the quarter, compared to analysts' expectations of $6.72 million. Corium International had a negative net margin of 155.21% and a negative trailing twelve-month return on equity of 276.89%.

What other stocks do shareholders of Corium International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Corium International investors own include Bristol Myers Squibb (BMY), Intelsat (I), Energy Transfer (ET), Iovance Biotherapeutics (IOVA), Exelixis (EXEL), SunCoke Energy Partners (SXCP) and Cypress Semiconductor (CY).

Company Calendar

• Last Earnings: 8/09/2018
• Today: 8/08/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CORI
• CIK: 1594337
• Web: www.coriumgroup.com
• Phone: 650-298-8255
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.79 million
• Net Margins: -155.21%
• Pretax Margin: N/A
• Return on Equity: -276.89%
• Return on Assets: -57.52%

Debt

• Debt-to-Equity Ratio: 2.83
• Current Ratio: 7.61
• Quick Ratio: 7.47

Sales & Book Value

• Annual Sales: $31.86 million
• Price / Sales: 14.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 28.18

Miscellaneous

• Outstanding Shares: 36,250,000
• Free Float: N/A
• Market Cap: $459.65 million
• Optionable: Optionable
• Beta: 0.87